(1-氨基甲酰基环戊基)氨基甲酸叔丁酯 | 223648-38-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1-氨基甲酰基环戊基)氨基甲酸叔丁酯
• 英文名称: 1-tert-butoxycarbonylamino-1-cyclopentanecarboxamide
• 英文别名: tert-butyl N-(1-carbamoylcyclopentyl)carbamate
• CAS: 223648-38-2
• 化学式: C₁₁H₂₀N₂O₃
• mdl: MFCD23378715
• 分子量: 228.291
• InChiKey: ITDQMUWECXSWDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-氨基甲酰基环戊基)氨基甲酸叔丁酯 在 盐酸 、 4-二甲氨基吡啶 、 sodium hydride 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 碘甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 98.0h， 生成 benzyl (2S)-2-[[(3R)-1-(1-carbamoylcyclopentyl)-2-oxopyrrolidin-3-yl]carbamoyl]pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and Dopamine Receptor Modulating Activity of Novel Peptidomimetics of l-Prolyl-l-leucyl-glycinamide Featuring α,α-Disubstituted Amino Acids

  摘要：

  In the present study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d were synthesized utilizing alpha,alpha-disubstituted amino acids. These analogues were designed to explore the conformational effects of constraints at the phi(3) and psi(3) torsion angles. Constrained conformations were verified by the use of X-ray crystallography and circular dichroism. The effects of Pro-Leu-Gly-NH2 analogues 3a-3d and 4a-4d on enhancing rotational behavior induced by apomorphine in the 6-hydroxydopamine-lesioned animal models of Parkinson's disease were studied. The ability of these peptidomimetics to increase the binding of agonist N-propylnorapomorphine (NPA) to the dopamine D-2 receptor was also examined. Extended analogue Pro-Leu-Deg-NH2 was the most active compound of this series. It was 10 times more potent and almost 2 times more effective than 1 in increasing apomorphine-induced rotations (56 +/- 15% at 1.0 mg/kg ip) and in enhancing [H-3]NPA specific binding (40%).

  DOI：

  10.1021/jm980656r
• 作为产物：
  描述：

  Boc-1-氨基环戊烷羧酸 在 氨 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 1.0h， 以66%的产率得到(1-氨基甲酰基环戊基)氨基甲酸叔丁酯
  参考文献：
  名称：

  Inhibitors of HCV replication

  摘要：

  化合物I的吲哚类化合物已被描述。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的人。还描述了包含这些化合物的不同形式和组成，以及制备这些化合物的方法。

  公开号：

  US20060046983A1

文献信息

• Inhibitors of HCV replication
  申请人：Hudyma W. Thomas

  公开号：US20060046983A1

  公开（公告）日：2006-03-02

  Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

  化合物I的吲哚类化合物已被描述。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的人。还描述了包含这些化合物的不同形式和组成，以及制备这些化合物的方法。
• Copper-catalyzed cross-coupling of amino acid-derived amides with (Z)-vinyl iodides: Unexpected solvent effect and preparation of plocabulin
  作者：Leiming Wang、Xinsheng Lei、Quanrui Wang、Yingxia Li

  DOI：10.1016/j.tet.2021.131953

  日期：2021.3

  A copper-catalyzed cross-coupling reaction of amino acid-derived amides and (Z)-vinyl iodide was studied to improve a key step in the synthesis of plocabulin, a novel microtubule destabilizer agent of marine origin. The study revealed a profound solvent effect with 1,2-dimethoxyethane (DME), which gave consistently high yields across a large variety of the amide and (Z)-vinyl iodide substrates. The

  研究了氨基酸衍生的酰胺与（Z）-乙烯基碘的铜催化交叉偶联反应，以改善合成新型海洋微管稳定剂plocabulin的关键步骤。这项研究表明，1,2-二甲氧基乙烷（DME）具有很强的溶剂作用，可在各种酰胺和（Z）-乙烯基碘化物底物上始终保持较高的收率。该方案已成功用于朴素蛋白的制备，并显着提高了产量。
• [EN] IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] IMIDAZOLYLE DIPHÉNYLE IMIDAZOLES INHIBITRICES DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009102325A1

  公开（公告）日：2009-08-20

  The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

  本公开涉及化合物式（I），组合物以及用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这种化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• Amidopyrazole Derivative
  申请人：Kanaya Naoaki

  公开号：US20070219210A1

  公开（公告）日：2007-09-20

  A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar 1 and Ar 2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxy carbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

  提供了一种血小板凝血抑制剂，它既不抑制COX-1也不抑制COX-2。该抑制剂是由通式（I）表示的化合物：其中Ar1和Ar2独立地表示一个5-或6-成员的芳香杂环基团，可选地取代1至3个取代基，或一个苯基，可选地取代1至3个取代基；R1表示较低的酰基，羧基，较低的烷氧羰基，较低的烷氧基，较低的烷基，可选地取代1或2个取代基的氨基甲酰基，可选地取代1或2个取代基的草酰基，可选地取代1或2个取代基的氧代草酰基，可选地取代1或2个取代基的氨基，可选地取代1或2个取代基的4-至7-成员脂环杂环基团，可选地取代1或2个取代基的苯基，或可选地取代1至3个取代基的5-或6-成员芳香杂环基团；R2表示氢原子，卤素基或类似物。
• BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS
  申请人：Jia Zhaozhong J.

  公开号：US20120142671A1

  公开（公告）日：2012-06-07

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

  本发明涉及公式I的化合物及其药学上可接受的盐、酯和前药，这些化合物是Syk激酶的抑制剂。本发明还涉及用于制备这些化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制Syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由Syk激酶活性介导的多种疾病，如非霍奇金淋巴瘤的方法。